Insilicos Announces Trial of Cardiovascular Diagnostic
Seattle, 6 September 2010 - Insilicos today announced that the company has been awarded a $1.2 million grant to evaluate Insilicos' PreClue diagnostic test for cardiovascular disease. The test will be given to 400 subjects with suspected cardiovascular disease, to predict future heart attacks in advance.
"We're excited to be moving into the clinic," said Insilicos Chief Scientist Bryan Prazen. "Our human results to date have been extremely encouraging. Now we'll get to see performance under more realistic clinical conditions."
"This is an important day for Insilicos," said president Erik Nilsson. "Our test has the potential to revolutionize the way cardiovascular patients are evaluated and treated. We look forward to this project with great enthusiasm."
Insilicos LLC is a biomarker discovery and diagnostic development company, concentrating on cardiovascular disease.
For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' 'PreClue," and 'Life Science Software' are trademarks of Insilicos LLC.
